Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.: Original article

Mycoses

Volumn 53, Issue 3, 2010, Pages 239-245

  Demchok, Joanne P ^a   Meletiadis, Joseph ^a   Roilides, Emmanuel ^a,b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Antifungal susceptibility; Combination therapy; Echinocandins; Triazoles

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ECHINOCANDIN; RAVUCONAZOLE; TRIAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BROTH DILUTION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG SYNERGISM; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIAZOLES;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS;

EID: 77950836148     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01700.x     Document Type: Article

References (21)

1. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother 2004 48 : 693 715. (Pubitemid 38280314)
2. Johnson MD, Perfect JR. Combination antifungal therapy: what can and should we expect? Bone Marrow Transplant 2007 40 : 297 306.
3. Manavathu EK, Alangaden GJ, Chandrasekar PH. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J Antimicrob Chemother 2003 51 : 1423 1425.
4. O'Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother 2006 58 : 1168 1176. (Pubitemid 44884135)
5. Patterson TF. Combination antifungal therapy. Pediatr Infect Dis J 2003 22 : 555.
6. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002 46 : 3039 3041.
7. Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006 194 : 1008 1018. (Pubitemid 44454087)
8. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993 36 : 421 424. (Pubitemid 24175353)
9. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004 64 : 1997 2020.
10. Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008 61 (Suppl. 1 i19 30.
11. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002 46 : 245 247. (Pubitemid 34031636)
12. Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005 49 : 4867 4875. (Pubitemid 41778896)
13. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003 98 : 292 299. (Pubitemid 36828453)
14. Dannaoui E, Lortholary O, Dromer F. In vitro evaluation of double and triple combinations of antifungal drugs against Aspergillus fumigatus and Aspergillus terreus. Antimicrob Agents Chemother 2004 48 : 970 978. (Pubitemid 38280351)
15. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002 46 : 2564 2568. (Pubitemid 34793464)
16. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003 187 : 1834 1843. (Pubitemid 36724481)
17. Singh N, Limaye AP, Forrest G et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006 81 : 320 326. (Pubitemid 43255714)
18. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995 39 : 1779 1783.
19. Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob Agents Chemother 2007 51 : 2053 2064. (Pubitemid 46903094)
20. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995 39 : 1907 1912.
21. Walsh TJ, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003 188 : 305 319. (Pubitemid 36898165)